Pfizer Licensing Agreement Renewal

Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, is pleased to announce that it has signed a renewal of its Licensing Agreement with Pfizer Inc. ("Pfizer").

Under the renewed agreement, Pfizer will continue to license Trellus Health's patient support educational content for inclusion within its inflammatory bowel disease ("IBD") digital application. The original agreement was entered into in the second quarter of 2024.

Dr. Marla Dubinsky, CEO and Co-founder of Trellus Health plc said: "We are excited to extend this agreement with Pfizer, which underscores both the continued engagement of their users with our content on the platform and the value of our resilience-driven approach and methodology. Alongside our recent Gastro Health Master Services Agreement, the extension of our collaboration with Johnson & Johnson, and the continued roll-out of TrialSet™ across clinical trials, this renewal further supports the applicability of our platform across the pharmaceutical lifecycle. We remain focused on advancing commercial discussions and converting pipeline opportunities into revenue."

As previously announced, the Company has reduced its monthly cash burn to an average of c. $300k as of March 2026. With this renewal, as well as a loan from Laurie Keefer, Ph.D.,the Company's scientific co-founder and co-inventor of the Company's resilience methodology, the Company expects its cash runway to extend into May 2026.

The Board remains supportive of the Company's commercial strategy and is engaged in ongoing discussions regarding a range of potential funding options to further extend the Company's cash runway.